stockportfolio.pro
Stocks / ALKS vs QGEN
ALKS vs QGEN
Alkermes plc and Qiagen N.V. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Alkermes plc (ALKS) | Qiagen N.V. (QGEN) | |
|---|---|---|
| Market cap | $7.3B | $7.6B |
| Revenue (latest FY) | $1.48B | $2.09B |
| Net income (latest FY) | $241.66M | $424.88M |
| Revenue growth (5y CAGR) | 7.3% | -0.8% |
| Net margin | 16.4% | 20.3% |
| Return on equity | 13.3% | 11.2% |
| P/E ratio | 49.0 | 18.8 |
| Dividend yield | — | 0.9% |
| Profitable years (of last 10) | 3 | 4 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open ALKS — free Open QGEN — freeFrequently asked questions
Which is bigger, ALKS or QGEN?
Qiagen N.V. is larger by market capitalization — $7.6B versus $7.3B.
Which grows faster, ALKS or QGEN?
Over the last five fiscal years, Alkermes plc grew revenue faster — 7.3%/yr versus -0.8%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.